Human Gene Therapy
Volume 31, Issue 11-12 / June 2020
The Impact of the COVID-19 Pandemic on the Biotech Industry
Published Online:18 May 2020
… In 2021, the biotech sector will have a valuation at or above the valuation it had in late 2019. Preclinical work will be robust. Clinical trials will be near the volume of a year earlier. The regulatory review of clinical trials will be more efficient. New biotech companies will raise needed capital, and the number of new IPOs will not be much different than in 2019. There will be an uptick in M&A activity as large pharmaceutical companies acquire smaller companies (for example, the decision announced by Alexion on May 5 that it would acquire Portola at a valuation much below that company’s value in mid-2019). Most important, the contributions of talented scientists both inside academe and in the industry will continue to initiate discovery programs, many of which will lead to new drugs in our endless battle against disease.